Incannex updates on Phase 2 results for IHL-42X and PSX-001; ATM shares unchanged since Aug 2025

Incannex Healthcare Inc.

IHL-42X Phase 2 OSA trial showed up to 83% reduction in AHI; 57.6% of participants reported improvement (78.6% low dose).
PSX-001 Phase 2 GAD trial met primary endpoint HAM-A and multiple secondary measures with sustained relief over 11 weeks, no SAEs.
ATM facility not utilized since Aug 28, 2025; total shares outstanding unchanged at 347,705,507.
Company prioritizing FDA engagement for pivotal development of IHL-42X and PSX-001, and exploring partnerships.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.